Risk factors for second acute myeloid leukemia/myelodysplastic syndrome among survivors of non-Hodgkin lymphoma

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Godley LA, Larson RA . Therapy-related myeloid leukemia. Semin Oncol 2008; 35: 418–429.

  2. 2

    Ramadan SM, Fouad TM, Summa V, Hasan SKH, Lo-Coco F . Acute myeloid leukemia developing in patients with autoimmune diseases. Haematologica 2012; 97: 805–817.

  3. 3

    Titmarsh GJ, McMullin MF, McShane CM, Clarke M, Engels EA, Anderson LA . Community-acquired infections and their association with myeloid malignancies. Cancer Epidemiol 2014; 38: 56–61.

  4. 4

    Kristinsson SY, Björkholm M, Hultcrantz M, Derolf ÅR, Landgren O, Goldin LR . Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. J Clin Oncol 2011; 29: 2897–2903.

  5. 5

    Anderson LA, Pfeiffer RM, Landgren O, Gadalla S, Berndt SI, Engels EA . Risks of myeloid malignancies in patients with autoimmune conditions. Br J Cancer 2009; 100: 6.

  6. 6

    Ballotti S, Chiarelli F, de Martino M . Autoimmunity: basic mechanisms and implications in endocrine diseases. Part II. Horm Res. 2006; 66: 142–152.

  7. 7

    Sweet RA, Cullen JL, Shlomchik MJ . Rheumatoid factor B cell memory leads to rapid, switched antibody-forming cell responses. J Immunol 2013; 190: 1974–1981.

  8. 8

    Zhang X, Ing S, Fraser A, Chen M, Khan O, Zakem J et al. Follicular helper T cells: new insights into mechanisms of autoimmune diseases. Ochsner J 2013; 13: 131–139.

  9. 9

    Porakishvili N, Mageed R, Jamin C, Pers JO, Kulikova N, Renaudineau Y et al. Recent progress in the understanding of B-cell functions in autoimmunity. Scand J Immunol 2001; 54: 30–38.

  10. 10

    McLaughlin P, Estey E, Glassman A, Romaguera J, Samaniego F, Ayala A et al. Myelodysplasia and acute myeloid leukemia following thearpy for indolence lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha. Blood 2005; 105: 4573–4575.

  11. 11

    Morrison VA, Rai KR, Peterson BL, Kolitz JE, Elias L, Appelbaum FR et al. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an Intergroup Study, Cancer and Leukemia Group B 9011. J Clin Oncol 2002; 20: 3878–3884.

  12. 12

    Tam CS, Seymour JF, Prince HM, Kenealy M, Wolf M, Januszewicz EH et al. Treatment-related myelodysplasia following fludarabine combination chemotherapy. Haematologica 2006; 91: 1546–1550.

  13. 13

    Benjamini O, Jain P, Trinh L, Qiao W, Strom SS, Lerner S et al. Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes. Leuk Lymphoma 2014; 56: 191–198.

  14. 14

    Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24: 3187–3205.

  15. 15

    Renauld JC . New insights into the role of cytokines in asthma. J Clin Pathol 2001; 54: 577–589.

Download references

Acknowledgements

This research was supported by the Intramural Program of the National Institutes of Health, National Cancer Institute.

Author information

Correspondence to L M Morton.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Lam, C., Curtis, R., Dores, G. et al. Risk factors for second acute myeloid leukemia/myelodysplastic syndrome among survivors of non-Hodgkin lymphoma. Leukemia 30, 1187–1190 (2016). https://doi.org/10.1038/leu.2015.248

Download citation

Further reading